{
  "id": 20790748,
  "title": "With Dupixent's Patent Clock Ticking, Sanofi Circles Insmed",
  "url": "https://urgent.news/2026/11/19/with-dupixents-patent-clock-ticking-sanofi-circles-insmed",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-19T18:57:22.000Z",
  "source": {
    "name": "Benzinga",
    "slug": "benzinga",
    "url": "https://www.benzinga.com/m-a/26/11/63450896/with-dupixents-patent-clock-ticking-sanofi-circles-insmed"
  },
  "original_language": "en",
  "account": "Sanofi is actively scouting a potential acquisition of Insmed Inc. (NASDAQ:INSM), a respiratory disease specialist, as it seeks new growth avenues to mitigate its dependency on the blockbuster drug Dupixent. Insmed's pipeline includes two commercial respiratory drugs: Brinsupri (brensocatib) and Arikayce (amikacin liposome inhalation suspension). The former treats non-cystic fibrosis bronchiectasis, while the latter targets refractory Mycobacterium avium complex (MAC) lung disease. In Q3, Brinsupri generated $400.1 million in sales, while Arikayce sales reached $124.4 million. Insmed is projected to achieve Brinsupri revenue of $1.35 billion to $1.4 billion in 2026, and Arikayce sales of $460 million to $470 million. The French pharmaceutical giant is also evaluating Inmed's treprostinil palmitil inhalation powder (TPIP) for four lung disease indications, as well as INS1148, INS1033, and next-generation DPP1 inhibitors in its early-stage pipeline.",
  "summary": "Insmed Inc. (NASDAQ:INSM) stock surged Thursday following a report that French pharmaceutical giant Sanofi SA (NASDAQ:SNY) is exploring a potential acquisition of the respiratory disease specialist . The potential acquisition comes as Sanofi seeks new growth opportunities to reduce its reliance on blockbuster drug Dupixent. Sanofi Explores Potential Insmed Takeover Bloomberg reported Thursday…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}